COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 868: Articles 8671-8680  | Next

Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2
Meher, K., Sivakumar, S., Kadiyala, G., Iyer, S., Vangala, S., Chandran, S., Saxena, U.
10.1101/2022.02.21.481267 — Posted: 2022-02-22
A novel intranasal administration adenoviral vector-based platform for rapid COVID-19 vaccine development
Yuan, Y., Gao, X., Ni, F., Xie, W., Fu, W., Zhang, G., Hu, H., Li, Y., Hu, Q., Huang, C., Liu, B., Liu, Y., Shen, Q., Liang, M.
10.1101/2022.02.21.481247 — Posted: 2022-02-22
Targeted Down Regulation Of Core Mitochondrial Genes During SARS-CoV-2 Infection
Guarnieri, J. W., Dybas, J. M., Fazelinia, H., Kim, M. S., Frere, J., Zhang, Y., Albrecht, Y. S., Murdock, D. G., Angelin, A., Singh, L. N., Weiss, S. L., Best, S. M., Lott, M. T., Cope, H., Zaksas, V., Saravia-Butler, A., Meydan, C., Foox, J., Mozsary, C., Kidane, Y. H., Priebe, W., Emmett, M., Meller, R., Singh, U., Bram, Y., tenOever, B. R., Heise, M. T., Moorman, N. J., Madden, E. A., Taft-Benz, S. A., Anderson, E. J., Sanders, W. A., Dickmander, R. J., Baxter, V. K., Baylin, S., Wurtele, E., Moraes-vieira, P., Taylor, D., Mason, C., Schisler, J. C., Schwartz, R. E., Beheshti, A., Wallace, D. C.
10.1101/2022.02.19.481089 — Posted: 2022-02-22 Discussion: Onsite
Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron
Benlarbi, M., Laroche, G., Fink, C., Fu, K., Mulloy, R. P., Phan, A., Ariana, A., Stewart, C. M., Prevost, J., Beaudoin-Bussieres, G., Daniel, R., Bo, Y., Yockell-Lelievre, J., Stanford, W. L., Giguere, P. M., Mubareka, S., Finzi, A., Dekaban, G. A., Dikeakos, J. D., Cote, M.
10.1101/2022.02.19.481107 — Posted: 2022-02-22
Omicron booster in ancestral strain vaccinated mouse augments protective immunities against both the Delta and Omicron variants
Jia, L., Zhou, Y., Li, S., Zhang, Y., Yan, D., Wang, W., Zhang, W., Wan, Y. m., Qiu, C.
10.1101/2022.02.19.481110 — Posted: 2022-02-22
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., Gouma, S., Hicks, P., Dysinger, S., Hicks, A., Sharma, H., Herring, S., Korte, S., KC, W., Oldridge, D. A., Erickson, R. I., Weirick, M. E., McAllister, C. M., Awofolaju, M., Tanenbaum, N., Dougherty, J., Long, S., D'Andrea, K., Hamilton, J. T., McLaughlin, M., Williams, J. C., Adamski, S., Kuthuru, O., Drapeau, E. M., Davenport, M. P., Hensley, S. E., Bates, P., Greenplate, A. R., Wherry, E. J.
10.1101/2022.02.20.481163 — Posted: 2022-02-22
Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules
Nersisyan, S., Zhiyanov, A., Zakharova, M., Ishina, I., Kurbatskaia, I., Mamedov, A., Galatenko, A., Shkurnikov, M., Gabibov, A., Tonevitsky, A.
10.1101/2022.02.21.481175 — Posted: 2022-02-22
SARS-CoV-2 Viroporins Activate The NLRP3-Inflammasome Via The Mitochondrial Permeability Transition Pore
Guarnieri, J. W., Angelin, A., Murdoch, D. G., Portluri, P., Lie, T., Wallace, D. C.
10.1101/2022.02.19.481139 — Posted: 2022-02-22
Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
Dicks, M. D. J., Rose, L. M., Bowman, L. A. H., Graham, C., Doores, K. J., Malim, M. H., Draper, S. J., Howarth, M., Biswas, S.
10.1101/2022.02.20.480711 — Posted: 2022-02-22
Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave
Shingleton, J., Dyke, S., Herrick, A., Finnie, T.
10.1101/2022.02.21.22271270 — Posted: 2022-02-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).